- Home
- SPT vs PRAX Comparison
SPT vs PRAX Comparison
Compare SPT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- PRAX
- Stock Information
- Founded
- SPT 2010
- PRAX 2015
- Country
- SPT United States
- PRAX United States
- Employees
- SPT N/A
- PRAX N/A
- Industry
- SPT Computer Software: Prepackaged Software
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- PRAX Health Care
- Exchange
- SPT Nasdaq
- PRAX Nasdaq
- Market Cap
- SPT 799.3M
- PRAX 950.8M
- IPO Year
- SPT 2019
- PRAX 2020
- Fundamental
- Price
- SPT $14.67
- PRAX $45.23
- Analyst Decision
- SPT Buy
- PRAX Strong Buy
- Analyst Count
- SPT 10
- PRAX 10
- Target Price
- SPT $27.70
- PRAX $93.30
- AVG Volume (30 Days)
- SPT 990.4K
- PRAX 391.2K
- Earning Date
- SPT 11-06-2025
- PRAX 11-05-2025
- Dividend Yield
- SPT N/A
- PRAX N/A
- EPS Growth
- SPT N/A
- PRAX N/A
- EPS
- SPT N/A
- PRAX N/A
- Revenue
- SPT $430,795,000.00
- PRAX $7,765,000.00
- Revenue This Year
- SPT $13.01
- PRAX N/A
- Revenue Next Year
- SPT $11.79
- PRAX $22.22
- P/E Ratio
- SPT N/A
- PRAX N/A
- Revenue Growth
- SPT 14.79
- PRAX 338.45
- 52 Week Low
- SPT $13.33
- PRAX $26.70
- 52 Week High
- SPT $36.30
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- SPT 46.00
- PRAX 51.74
- Support Level
- SPT $13.80
- PRAX $37.25
- Resistance Level
- SPT $14.90
- PRAX $40.69
- Average True Range (ATR)
- SPT 0.65
- PRAX 2.55
- MACD
- SPT 0.06
- PRAX 0.27
- Stochastic Oscillator
- SPT 45.16
- PRAX 74.51
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.